Neuroscience

Our Commitment to Neuroscience

Neuroscience is advancing at an unprecedented rate and we are proud to be at the forefront of this transformation. Our focus is on enabling children and adults suffering from debilitating and degenerative neurological disorders to take back control of their lives, and our long‐term commitment to advancing neuroscience and toxins research is evidenced by over 25 years of clinical experience.

Neuroscience is central to Ipsen’s internal innovation and external partnering, integral to the company’s overall strategy, and a key driver of long‐term value and growth.

Key Facts

In 2021, our neuroscience division achieved sales of €440.7m, equivalent to 15.4% of our income.

Neurotoxins

Since 1994, Ipsen has focused on pioneering research in neurotoxins. People suffering from neurological disorders need treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, cervical dystonia, cerebral palsy, hemifacial spasm, and blepharospasm. Additionally, our work in neurotoxins extends to aesthetic indications with our partner Galderma, including the reduction of glabellar lines (frown lines).

Neurodegenerative, Rare Neuroinflammatory and Movement Disorders

Neuroscience is deeply rooted within Ipsen as a key strategic driver for our business. Through our strategy in external innovation, we are actively expanding our pipeline into neurodegenerative disorders and rare neuroinflammatory and movement disorders with the goal of improving the lives and health outcomes of people living with neurological conditions around the world.

Our Neuroscience Pipeline

As the only company with recombinant botulinum neurotoxins in our portfolio and in active clinical development, our R&D centers around the world are pioneering research in neuroscience. Recombinant toxins, with longer duration of action in preclinical models, could potentially give healthcare providers the ability to choose the most appropriate neurotoxin for their patients. Recognizing the need for new, longer-lasting treatment options, Ipsen has leveraged its knowledge and more than 25 years’ experience of native botulinum neurotoxins and R&D capabilities to harness the power and potential of toxin biology and to pioneer innovation in toxin therapy.

In addition to our expertise in neurotoxins, our strategy includes research into rare neurodegenerative disorders such as Huntington’s disease, rare neuroinflammatory disorders, movement disorders such as Parkinson’s disease, and rare neurodevelopmental disorders such as Angelman syndrome. Our strong development capabilities cover all stages of the drug development process, and we have a successful track record of global regulatory approvals and accelerated pathways, making Ipsen an ideal partner for neuroscience innovation.

Learn more about our pipeline

Working with patients and healthcare providers

Ipsen’s priority is to improve the lives of patients, their caregivers, their communities and, ultimately, society. We seek opportunities to go further and reach more patients, advocacy groups and healthcare providers because every patient is unique and requires their own support system. We have built strong, long-term partnerships with patient organizations and healthcare providers, and we are a leader in thought leadership and medical education, including:

Dystonia Patient Organizations

We collaborate with several patient organizations around the world, such as Dystonia Europe, to ensure we are responding to patient needs. We are proud sponsors of the David Marsden’s Award which is presented every year to encourage and drive research on dystonia, especially by young scientists in Europe.

Stroke Alliance for Europe

SAFE is a non-profit-making organization that represents a range of stroke support organizations from across Europe. Ipsen has been collaborating with SAFE on projects to raise awareness on stroke and associated conditions, such as post-stroke spasticity. Ipsen notably sponsored the Burden of Stroke in Europe Report and Stroke Action Plan For Europe.

European Federation of Neurological Associations

Ipsen supports EFNA’s activities, notably to raise awareness on the impact of neurological disorders and make sure that decision-makers recognize the increasing burden of neurological disorders. Ipsen sponsors the MEP Interest Group on Brain Mind and Pain that focuses on eradicating the stigma, isolation and discrimination linked with neurological disorders.

Partnering

We believe that great partnerships create great possibilities. We are on a mission to deliver at least one new molecular entity or meaningful indication each year and collaborations with other like-minded innovators are key for the next phase of our growth.

Investors

Visit our dedicated investor section to find more information on financial results, our financial calendar and more.

Choose your location:

Choose a Language

Our Commitment to Neuroscience

In 2021, our neuroscience division achieved sales of €440.7m, equivalent to 15.4% of our income.

We have over 25 years of experience in neurotoxins.

We are the only company with recombinant botulinum neurotoxins in our portfolio.

Our partnership with Galderma, which has been extended until 2036, means that together we represent 75% of the world market for neurotoxins in aesthetic indications.

We have over 1000 employees supporting neuroscience.

Our production sites have full end-to-end capabilities, from development, active ingredient and aseptic manufacturing, to testing, packaging and distribution.

Our Areas of Expertise